Overview


According to FutureWise analysis the market for anticoagulants in 2023 is US$ 32.29 billion, and is expected to reach US$ 55.52 billion by 2031 at a CAGR of 7.00% over the forecast period of 2023-2031.

Anticoagulant medicines (also known as blood thinners) are chemical agents that inhibit or diminish blood coagulation and lengthen the time it takes for blood to clot. These medications are mostly used in patients with a high risk of blood clots in illnesses such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. The global anticoagulants industry is expected to grow significantly during the forecast period, owing to an increase in the prevalence of venous thromboembolism (VTE) and cardiovascular disorders, increased adoption of novel oral anticoagulants (NOACs), and increased awareness of NOACs in the developing region. Furthermore, an increase in the number of obese and aged individuals, increased unmet requirements, and a surge in demand for innovative therapies all contribute to market growth. However, the greater price of NOACs and the absence of NOAC antidotes restrict market expansion. This is due to a rise in the prevalence of chronic illnesses as well as technological breakthroughs in the production of anticoagulant products. Anticoagulants are used to treat and prevent blood clots, which can block blood vessels (an artery or a vein) and cause significant consequences such as heart attack and stroke because the clot restricts the flow of blood to vital organs.

Furthermore, technical progress in the creation of anticoagulant products is projected to drive the market. According to the study "Technology Advancements in Blood Coagulation Measurements for Point-of-Care Diagnostic Testing," published in the Frontier in Biotechnology and Bioengineering, advanced technologies such as microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS) have been used to develop highly accurate, robust, and cost-effective anticoagulant products.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Anticoagulants Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Anticoagulants Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Bayer AG
  • Aspen Holdings
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Limited
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline
  • Pfizer, Inc.
  • Sanofi S.A.
  • Johnson and Johnson
  • Portola Pharmaceuticals, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Anticoagulants Market:

  • In December of 2022, Johnson & Johnson successfully finalized its acquisition of Abiomed, a renowned innovator in revolutionary technologies for heart, lung, and kidney support.
  • Furthermore, in June 2021, Boehringer Ingelheim, a leading pharmaceutical firm, announced the U.S. FDA approval of its Pradaxa (dabigatran etexilate) oral pellets for treating venous thromboembolism in children aged three months to under 12 years. This regulatory milestone significantly expanded the company's clientele

The increasing prevalence of cardiovascular disease, including atrial fibrillation and deep vein thrombosis, is driving the market growth. With a growing aging population, the disease burden for age-related disorders is also increasing, and demand for anticoagulant therapies contributes to the market growth. Growing awareness among healthcare providers and patients about the risks associated with thrombotic disease leads to early diagnosis and management of the disease and drives the market. Ongoing research and developments in anticoagulant medications, particularly in the introduction of novel oral anticoagulants, are creating and expanding new opportunities for the market and are propelling the revenue of the market growth. In addition, funds raised by the public and private organizations also contribute to the market growth.

However, the high cost of anticoagulant medications, especially novel oral anticoagulants, can be a barrier to market growth as it decreases the accessibility and affordability for the lower strata of society and in developing regions with inadequate insurance coverage and healthcare services. Antiplatelet medications provide an alternative to anticoagulant drugs and constrain market growth.

By Drug Class

  • NOACs
    • Bevyxxa
    • Eliquis
    • Lixiana and Savaysa
    • Pradaxa
    • Xarelto
  • Heparin and LMWH
  • Vitamin K Antagonist
  • Others

By Route of Administration

  • Injectable Anticoagulant
  • Oral Anticoagulant

By Application

  • Stroke
  • Atrial Fibrillation
  • Pulmonary Embolism (PE)
  • Deep vein thrombosis (DVT)
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the rising burden of cardiovascular disorders, which has increased demand for anticoagulants in this region. An increased geriatric patient pool, which is more prone to the prevalence of chronic diseases, often requires anticoagulants, expanded healthcare infrastructure, a surge in healthcare expenditure, and increased research and development is occurring, which is enhancing the treatment modalities and interventions with more innovations in this region which is driving the market.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on Anticoagulants Market By Drug Class, By Route of Administration, By Application, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anticoagulants Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anticoagulants Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anticoagulants Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anticoagulants Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. NOACs
         1.1. Bevyxxa
         1.2. Eliquis
         1.3. Lixiana and Savaysa
         1.4. Pradaxa
         1.5. Xarelto
        2. Heparin and LMWH
        3. Vitamin K Antagonist
        4. Others

  • 8.   Anticoagulants Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injectable Anticoagulant
        2. Oral Anticoagulant

  • 9.   Anticoagulants Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Stroke
        2. Atrial Fibrillation
        3. Pulmonary Embolism (PE)
        4. Deep vein thrombosis (DVT)
        5. Others

  • 10.   Anticoagulants Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 11.   North America Anticoagulants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Anticoagulants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Anticoagulants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Anticoagulants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Bayer AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aspen Holdings
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Boehringer Ingelheim GmbH
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Stanford Medicine
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bristol-Myers Squibb Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sanofi S.A.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Johnson and Johnson
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Portola Pharmaceuticals, Incs
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Related Market

Anticoagulant Therapeutic Drug Monitoring Assay Kits Market

Read More

Anticoagulant Reversal Drugs Market

Read More

Anticoagulation Therapy Devices Market

Read More
Partner

Our Clients